# Monte Rosa Therapeutics, Inc. (GLUE) · Edgar & Edgarette company card

> Monte Rosa Therapeutics (GLUE) grew revenue 63.5% in FY2025 to $124 million, operating margin -43.8% against a -15.8% median for biological products, (no diagnostic substances), equity 51.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1826457 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/GLUE) · [JSON](https://www.pops4.com/boards/company/GLUE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $124M |
| Revenue growth, 1 year | 63.5% |
| Revenue growth per year | — |
| Operating margin | -43.8% (prior year -107.3%) |
| Net margin | -31.2% |
| Operating cash flow | −$23M |
| Capital spending | $5M |
| Free cash flow | −$27M |
| Cash | $130M |
| Long-term debt | — |
| Total assets | $449M |
| Total equity | $233M |
| Equity ÷ assets | 51.9% |
| Return on equity | -16.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.67 (grey zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -43.8% in FY2025

## Edgarette's reading

Exposure: revenue $123.7M (FY2025). Experience: revenue up 63.5% on the year; operating margin -43.8%, up from -107.3%. Soundness: equity 51.9% of assets, return on equity -16.6%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $159.5M and $256.4M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -43.8% against a -15.8% median; growth 63.5% against 21.4%.

Range logged 2026-09-20, receipt e54c903925d68dec, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-02-10 ([filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526044616/0001193125-26-044616-index.htm))

## Recent filings

- 8-K · filed 2026-10-01 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526409833/0001193125-26-409833-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/0001193125-26-384360-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/0001193125-26-336711-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/0001193125-26-336681-index.htm)
- 8-K · filed 2026-06-11 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/0001193125-26-267465-index.htm)
- 10-Q · filed 2026-05-07 · [filing](https://www.sec.gov/Archives/edgar/data/1826457/000119312526210358/0001193125-26-210358-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001826457.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1826457

## Cite

POPS4, Edgar & Edgarette: Monte Rosa Therapeutics, Inc. (GLUE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/GLUE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.